BCG Apogepha® 100 mg
Non-muscle-invasive urothelial carcinoma of the bladder
ApprovedActive
Key Facts
Indication
Non-muscle-invasive urothelial carcinoma of the bladder
Phase
Approved
Status
Active
Company
About Apogepha
Apogepha is a century-old, private German pharmaceutical company with a deep specialization in urology. It has a commercial-stage portfolio spanning small molecule drugs, medical devices like BCG for bladder cancer, and consumer-facing nutraceuticals for conditions such as benign prostatic hyperplasia (BPH) and cystitis. The company leverages its heritage and focus on urology to maintain a strong presence in the German-speaking market, supported by continuous product introductions and active engagement with the medical community through scientific events.
View full company profile